Pfizer Secures FDA Approval for Intranasal Migraine Spray

March 10, 2023

Pfizer announced that it received approval from the US Food and Drug Administration (FDA) for its intranasal migraine spray Zavzpret. The drug was acquired by Pfizer in its acquisition of Biohaven, joining Pfizer’s lineup of migraine drugs. The approval comes after clinical trial data showed that the spray yielded significant improvements in acute pain relief for users.

According to Beth Snyder Bulik, “Zavzpret was more effective than placebo on 13 of the 17 secondary endpoints, including relief beginning as early as 15 minutes and sustained relief from two to 28 hours. It did not have a significant difference on the endpoint of return to normal function at 15 minutes which was the 14th endpoint and so the remaining endpoints were not formally tested, Pfizer said.”

To read more, click here.